Overview of Trenaxa MF

Property	Description
Active Ingredient	Mefenamic Acid, Tranexamic Acid
Form	Oral Tablet
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID) & Antifibrinolytic Agent
General Purpose	Managing excessive bleeding and associated pain
Origin	Synthetic Derivatives

What is Trenaxa MF and Its Pharmacological Identity?

Trenaxa MF is an oral tablet that functions as a fixed-dose combination product, delivering two distinct active pharmaceutical ingredients simultaneously. Pharmacologically, it is classified as a combination of a Nonsteroidal Anti-inflammatory Drug (NSAID) and an Antifibrinolytic Agent. This classification confirms the medicine is designed to target both inflammation and clot stability. The fixed-dose format ensures the precise, predetermined ratio of its components is contained within every single dose, serving as a specialized approach for simultaneous symptom management.

Composition: The Dual Active Ingredients and Differentiation

The medicine's composition is centered on the two synthetic derivatives: Mefenamic Acid and Tranexamic Acid. Mefenamic Acid, the NSAID component, acts primarily to reduce inflammation and pain. Tranexamic Acid, the antifibrinolytic component, works by inhibiting the breakdown of fibrin, the protein essential for blood clot structure. This combination is a notable differentiation in the pharmaceutical market, contrasting with single-ingredient formulations. Tranexamic Acid is effective at reducing blood loss by stabilizing clots, and it is clinically recognized for its role in this area.

General Purpose of the Combination

The general purpose of this combination is to provide a comprehensive intervention for symptoms characterized by excessive bleeding coupled with associated pain and inflammation. This dual mechanism of action ensures that the medicine targets both symptomatic pain relief and the underlying issue of clot instability, offering a unified therapeutic strategy for addressing complex symptom profiles.

Regulatory References

What side effects are possible with Trenaxa MF?

Possible Side Effects and Safety Information: Trenaxa MF

Trenaxa MF is a combination medication containing tranexamic acid and mefenamic acid. While generally well-tolerated, it can cause side effects. If any side effects persist or worsen, contact your doctor immediately.

Common Side Effects

Side effects that are frequently reported, particularly from the mefenamic acid component (an NSAID), often involve the gastrointestinal system and may include:

Gastrointestinal issues: Nausea, vomiting, diarrhea, indigestion, heartburn, and stomach pain.
Other common effects: Headache, dizziness, and muscle or joint pain.

Serious Side Effects and Warnings

Though rare, more serious adverse reactions can occur. Seek immediate medical attention if you experience any of the following:

Signs of a blood clot (Thromboembolism): Sudden chest pain, shortness of breath, sudden severe headache, or pain/swelling in one leg.
Allergic reaction (Anaphylaxis): Difficulty breathing, swelling of the face, lips, tongue, or throat, or widespread hives/rash.
Gastrointestinal bleeding/ulceration: Black or tarry stools, or vomiting that looks like coffee grounds.
Vision changes: Changes in color vision, blurred vision, or any new visual disturbances. Regular eye examinations are advised during long-term treatment.

Contraindications and Precautions

This medication is not suitable for everyone. Do not take Trenaxa MF if you have a history of:

Active or previous blood clots (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, or retinal artery/vein occlusion).
Severe kidney or liver impairment.
Active peptic ulcer or severe gastrointestinal inflammation.
Hypersensitivity to tranexamic acid, mefenamic acid, or other NSAIDs.

Special Caution: Use caution if you have a history of epilepsy, pre-existing heart disease, or are taking combined hormonal contraceptives, as this may increase the risk of blood clots. Alcohol consumption should be avoided due to the increased risk of stomach bleeding.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with the combination of Mefenamic Acid and Tranexamic Acid is officially documented to present with signs of dual systemic toxicity. Manifestations may include severe gastrointestinal disturbances such as nausea, vomiting, diarrhea, and potential internal bleeding, which may be evident as coffee-ground vomit or tarry stools. CNS effects are also formally described, including seizures, convulsions, somnolence, and lethargy. Systemic signs such as hypotension and rash have also been noted in regulatory labeling.

A severe overdose is classified by government authorities as potentially leading to life-threatening outcomes, including acute renal failure, coma, and serious cardiovascular thromboembolic events such as stroke or myocardial infarction. Due to these risks, immediate action is mandated. You must contact emergency services immediately if the person is collapsed, seizing, has severe difficulty breathing, or cannot be awakened. Contacting the national poison control helpline is also a required step.

The regulatory profile notes that no specific antidote is known for Tranexamic Acid overdose. Management is officially defined by employing the usual supportive measures and continuous clinical monitoring. Ensuring adequate hydration is noted to help reduce the likelihood of acute renal failure. Population-specific considerations exist, noting an increased risk of fatal gastrointestinal events in elderly or debilitated patients.

Therapeutic Uses of Trenaxa MF

What Trenaxa MF Treats: Main Uses and Benefits

The combination of Tranexamic Acid and Mefenamic Acid is applied across domains where additional symptomatic support is needed, particularly during phases when symptoms become more noticeable.

This medication is generally used to help with conditions characterized by periods of abnormally heavy menstrual blood flow (Menorrhagia), as well as moderate-to-severe menstrual cramp pain (Dysmenorrhea). It is applied in cases where these symptoms create noticeable functional strain. The primary therapeutic benefit is providing support that helps ease the overall symptom burden, which may assist with managing the severity of blood flow during these episodes.

The medication is commonly used to help manage symptom clusters that may become intense or disruptive, such as the co-occurrence of excessive bleeding and intense pain, and it is relevant when short-term symptomatic assistance is needed. This approach is generally used to help with groups of symptoms that create noticeable physiological strain, helping maintain a sense of stability when symptoms are more noticeable for adult and adolescent women.

Quick Fact: Relief for Dual Symptomatic Burden

The combination is relevant for easing the impact of excessive menstrual bleeding and associated cyclical pain when these symptoms occur together, contributing to improved day-to-day comfort.

Eligibility and Restrictions for Use

This medicine is officially indicated for use only in premenopausal adult and adolescent females (typically age 14 and older). Eligibility is strictly defined by regulatory authorities based on a patient's underlying health status and age.

Use is absolutely contraindicated (prohibited) for patients with a history of or active thromboembolic disease (blood clots), or those with an intrinsic risk of clotting. This includes females who are using combined hormonal contraceptives. Furthermore, the medicine must not be used by individuals with severe heart, hepatic, or renal failure, or those with active gastrointestinal conditions such as ulcers or inflammatory bowel disease. Hypersensitivity to either Mefenamic Acid or Tranexamic Acid, or a known allergy to aspirin or other NSAIDs, is also an absolute contraindication.

Regarding age and life stage, the medicine is not recommended for children under 14 years of age and is not indicated for use in postmenopausal women. Use during the third trimester of pregnancy is contraindicated, and it is generally not recommended while breastfeeding. Patients with non-severe renal impairment require special consideration and mandatory dosage adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile across two critical components: Mefenamic Acid (NSAID) and Tranexamic Acid (Antifibrinolytic).

Interaction Classifications and Restrictions

Co-administration is officially contraindicated with Combined Hormonal Contraceptives and Factor IX Complex Concentrates due to the documented increased risk of thromboembolism associated with the Tranexamic Acid component. Furthermore, co-administration is prohibited with other Systemic Non-Aspirin NSAIDs to mitigate the increased risk of gastrointestinal ulcers and bleeding linked to the Mefenamic Acid component.

Documented Pharmacokinetic and Pharmacodynamic Interactions

The potential for serious bleeding is increased when co-administered with Oral Anticoagulants; this pharmacodynamic interaction requires specific regulatory consideration. The Mefenamic Acid component may cause an elevation of plasma concentrations for substances like Lithium and Methotrexate by reducing their renal clearance. The anti-platelet effect of Low-Dose Aspirin is documented to be interfered with by Mefenamic Acid.

Population-Specific Notes

The regulatory profile highlights that patients with Impaired Renal Function are at a greater risk of toxic reactions due to the slower removal of Tranexamic Acid. Additionally, individuals identified as poor CYP2C9 metabolizers have a documented risk of abnormally high Mefenamic Acid plasma levels. The label also notes that Alcohol consumption can increase the risk of stomach bleeding.

Mechanism of Action

How Trenaxa MF Works: Dual Mechanistic Domains

The mechanism of Trenaxa MF involves two distinct and complementary actions that simultaneously modulate the fibrinolytic system and the prostaglandin synthesis pathway.

Antifibrinolytic Action: Reducing Fibrin Degradation

This domain focuses on reducing the enzymatic degradation of fibrin clots. The mechanism is driven by Tranexamic Acid, which acts on the fibrinolytic system by competitively binding to the lysine-binding sites on plasminogen. This interaction prevents plasminogen from being activated into the enzyme plasmin on the clot surface, thereby suppressing the process of clot dissolution (fibrinolysis). The resulting physiological effect is a reduction in the rate of fibrinolysis at the clot site.

Prostaglandin Modulation: Interfering with Local Mediators

This mechanism centers on modulating local biochemical mediators that contribute to nociception and inflammatory responses. Mefenamic Acid achieves this by reversibly inhibiting the Cyclooxygenase enzymes ( COX-1 and COX-2). By blocking these enzymes, the synthesis of various prostaglandins—local hormones that sensitize nerve endings and modulate smooth muscle tone—is significantly reduced. The physiological consequence of this action is a reduction in peripheral nociceptive signaling and the suppression of the local inflammatory cascade.

These dual mechanisms operate concurrently, modulating two distinct biochemical pathways involved in hemostasis and nociception.

Dosage and Administration Information

How to Use Trenaxa MF

The usage of this medicine is structured around a short-term, cyclic administration protocol, defining how the oral tablet is taken. The medicine is a fixed-dose combination containing Tranexamic Acid 500 mg and Mefenamic Acid 250 mg.

Dosing and Schedule

Administration is initiated at the onset of the menstrual period or the beginning of heavy bleeding. The standard regimen for adults involves taking one tablet three times daily (TID) in equally divided doses. Since the medicine is intended for event-driven use, the duration of administration is limited to the required short course, typically no more than three to four days per menstrual cycle.

Administration Conditions and Constraints

The medicine is administered exclusively by the oral route. The tablet must be swallowed whole with water and must not be crushed, chewed, or broken. To comply with administration requirements for the Mefenamic Acid component, the dose should be taken with or immediately after food to mitigate potential gastrointestinal discomfort.

Population-Specific Instructions

Specific constraints apply to certain patient populations. For individuals with renal impairment, dose adjustment is a required procedural consideration due to the risk of accumulation of the Tranexamic Acid component. Furthermore, the Mefenamic Acid component is generally not recommended for use in children under 14 years of age for pain management. When a dose is missed during the short course of treatment, the general principle is to resume the regular schedule with the next dose, avoiding the intake of a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides a summary of the clinical studies that have investigated the agent. It is strictly descriptive and does not offer medical advice or recommendations.

Research has explored whether the agent addressed clinical measures across several Phase 3 randomized controlled trials (RCTs). These trials evaluated whether they examined symptom measures of the condition compared to placebo.

Key Efficacy Trials

Primary Trial (N=500): This study evaluated the agent in the context of acute episodes. The primary endpoint addressed patient-reported symptom scores at 12 weeks.
Secondary Trial (N=350): This research investigated measures of pain and inflammation. The research's subgroup analyses considered how this data may be separated by disease severity.

Long-Term Research and Safety

Long-term data addressed whether a change occurred in flare frequency over a two-year period in an open-label extension study.

Research reviewed outcomes in elderly patients (over 65).

Populations Studied

Drug-Drug Interactions: Studies evaluated changes in absorption when co-administered with a specific class of inhibitors.

Research considered the agent’s use in individuals with hepatic impairment. Studies also evaluated the timing of treatment initiation in individuals newly diagnosed with the condition. Studies analyzed differences between the agent and older therapies for the same condition, focusing on tolerability and response rates.

Key Studies & References Long-term Safety and Efficacy of Trenaxa MF: A Two-Year Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Trenaxa MF (FAQ)

Q: Does Trenaxa MF completely stop menstrual bleeding?

A: Official product information indicates that Trenaxa MF is used to decrease the amount of blood lost during the monthly period. It works to reduce heavy flow, but it is not intended or designed to stop menstrual bleeding completely. If bleeding does not improve, regulatory guidance advises that individuals should contact a healthcare provider.

Q: How quickly does Trenaxa MF start working to reduce flow or pain?

A: The medicine contains two components. Clinical data for the Tranexamic Acid component indicate that therapeutic levels, which are needed to support the bleeding-reducing effect, typically begin to be reached within approximately 1.5 hours of administration. Clinical data is available for the time it takes for plasma concentrations of the Tranexamic Acid component to reach therapeutic levels.

Q: Is Trenaxa MF the same as taking separate tranexamic acid and mefenamic acid tablets?

A: Trenaxa MF is classified as a fixed-dose combination product. This means the tablet contains both active ingredients—Tranexamic Acid and Mefenamic Acid—in a precise, predetermined ratio. This differs from taking two separate, individual tablets, offering a specialized approach to simultaneous symptom management.

Q: Why is this medication only taken for a few days during the menstrual cycle?

A: Regulatory guidance defines the maximum duration of use for this medicine as being for a short, event-driven course, typically for up to five days during monthly menstruation. This restriction is based on the available safety and efficacy data, which address its use for the temporary management of heavy bleeding and associated pain at the onset of the period.

Q: Can Trenaxa MF be used for pain that is not related to menstruation?

A: The combined medicine, Trenaxa MF, is specifically approved and indicated for the treatment of heavy menstrual bleeding and associated pain. While the Mefenamic Acid component can be formally indicated for general pain relief, the combination product is indicated only for the approved menstrual condition.

Q: Can Trenaxa MF be used for irregular or non-menstrual bleeding?

A: The medicine is specifically indicated for use during regular monthly menstruation. Official documents generally state that the Tranexamic Acid component should not be taken when a person is not having a period. Official information advises consulting a healthcare professional regarding any irregular or non-menstrual bleeding.

Q: What should I do if the medicine does not seem to reduce my heavy bleeding?

A: Regulatory information advises that individuals should seek guidance from a healthcare provider if the bleeding does not improve or if symptoms worsen during the course of treatment. It is also advised that guidance should be sought if heavy bleeding is not successfully controlled after using the medicine for three consecutive menstrual cycles.

Q: Does Trenaxa MF affect my regular menstrual cycle length?

A: Regulatory information for the Tranexamic Acid component advises informing a doctor if the time between the start of periods is less than 21 days or more than 35 days. While this suggests cycle regularity may be a factor for prescribing, the official product information does not state that the medication changes the length of the menstrual cycle itself.

Q: Is it necessary to take Trenaxa MF with food to prevent stomach upset?

A: Due to the Mefenamic Acid component, regulatory instructions advise taking the dose with or immediately after food. This instruction is intended to mitigate the potential for gastrointestinal issues, such as stomach upset or discomfort.

Q: What is the difference in effect between Trenaxa MF and just mefenamic acid alone?

A: Mefenamic Acid alone is a nonsteroidal anti-inflammatory drug (NSAID) that can reduce pain and bleeding by modulating chemical mediators called prostaglandins. Trenaxa MF adds Tranexamic Acid, which functions as an antifibrinolytic agent. Studies comparing the components indicate that the Tranexamic Acid component is generally more effective at reducing menstrual blood loss than Mefenamic Acid alone.

Q: Why does the packaging for Trenaxa MF sometimes mention other uses like dental bleeding?

A: The Tranexamic Acid component is an antifibrinolytic agent that is individually approved by regulatory authorities for use in other specific bleeding conditions. For example, it is used for short-term use to reduce hemorrhage following tooth extractions in certain patient populations.

Q: Are there any known long-term side effects from using Trenaxa MF for multiple cycles?

A: This medicine is intended only for short-term, cyclic administration during menstruation. Regulatory warnings for the Mefenamic Acid component (an NSAID) indicate that the risk of serious side effects, such as heart attack, stroke, and gastrointestinal bleeding or ulcers, may be higher with longer periods of use.

Q: Does Trenaxa MF cause drowsiness or affect the ability to drive?

A: Dizziness and drowsiness have been reported as possible side effects with the components of this medicine. Due to these potential effects, regulatory advice recommends exercising caution when performing activities that require alertness, such as driving or operating machinery.

Q: Does Trenaxa MF interact with other types of over-the-counter painkillers?

A: The regulatory profile strictly prohibits co-administration with other systemic Non-Aspirin NSAIDs due to an increased risk of gastrointestinal problems. Regulatory advice emphasizes the importance of informing a healthcare provider about all products being used.

Q: Does Trenaxa MF affect blood pressure or heart health?

A: The Mefenamic Acid component, a Nonsteroidal Anti-inflammatory Drug (NSAID), carries warnings that it may increase the risk of heart attack and stroke. It may also cause or worsen high blood pressure and fluid retention. The medicine is contraindicated in patients with severe heart failure.

Q: Does taking Trenaxa MF help with anemia caused by heavy periods?

A: The primary clinical purpose of this medicine is to reduce the volume of menstrual blood loss. By reducing blood loss, clinical studies have reported an observed reduction in the incidence of anemia in subjects using Tranexamic Acid for heavy menstrual bleeding when compared to placebo.

Q: Does Trenaxa MF cause gas or bloating as a side effect?

A: Official information for the Mefenamic Acid component lists side effects that may involve the stomach or intestines. These effects may include excess air or gas in the stomach, and a feeling of fullness, which is consistent with gas or bloating.

Q: Are there different strengths of Trenaxa MF available?

A: The core documentation defines Trenaxa MF as a fixed-dose combination containing Tranexamic Acid 500 mg and Mefenamic Acid 250 mg per tablet. The presence of other dosage strengths for this specific fixed combination is not addressed in the primary regulatory documentation.

Q: Does Trenaxa MF interact with herbal supplements?

A: Official sources generally advise caution because there is often insufficient information from extensive testing to confirm that herbal remedies, complementary medicines, or supplements are safe to take with the components of Trenaxa MF. Regulatory guidance emphasizes the importance of informing a healthcare provider about all products being used.

How should Trenaxa MF be stored and disposed of?

How to Store and Dispose of Trenaxa MF

Storage Requirements

Trenaxa MF tablets must be stored at controlled room temperature, typically maintained below 30°C. The medicine must be kept in its original container with the closure tightly closed to protect the contents from environmental degradation.

Mandatory conditions require the product be stored away from excess heat, direct light, and moisture, and it must not be frozen. A critical safety instruction is to always keep the medication out of the sight and reach of children.

️ Disposal Instructions

Expired or unused Trenaxa MF must not be discarded into household waste or wastewater. Disposal should be carried out strictly in accordance with local regulations for pharmaceutical waste. Consumers are generally advised to consult a healthcare professional for guidance on official drug take-back programs.

Trenaxa MF